secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2024-10-16T23:59:59+00:00
Accession:  0001104659-24-108950
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA places clinical hold on Novavax's combo COVID-flu and standalone flu vaccines after motor neuropathy SAE
--------------------------------------------------------------------------------

- FDA placed clinical hold on Novavax's IND for CIC and standalone influenza vaccine candidates.
- Hold triggered by spontaneous report of serious adverse event: motor neuropathy in a single Phase 2 participant.
- Participant received vaccine Jan 2023; trial completed Jul 2023; SAE reported Sep 2024.
- Clinical hold may delay initiation of Phase 3 immunogenicity trial for CIC and influenza vaccine.
- COVID-19 IND for Novavax's COVID-19 vaccine is not impacted by the clinical hold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924108950/0001104659-24-108950-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465924108950/tm2426249d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-108950

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer